XML 17 R4.htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
Consolidated Statements of Loss and Comprehensive Loss
$ in Thousands
 3 Months Ended 10 Months Ended 12 Months Ended
Mar. 31, 2024
$ / shares
Mar. 31, 2024
EUR (€)
shares
Mar. 31, 2024
USD ($)
shares
Mar. 31, 2023
$ / shares
Mar. 31, 2023
EUR (€)
shares
Mar. 31, 2023
USD ($)
shares
Dec. 31, 2022
EUR (€)
Dec. 31, 2023
EUR (€)
shares
Dec. 31, 2023
USD ($)
$ / shares
shares
Dec. 31, 2022
USD ($)
$ / shares
shares
Revenue     $ 18,031     $ 19,319     $ 76,071 $ 33,401
Cost of sales     14,177     13,973     58,333 20,150
Gross profit     3,854     5,346     17,738 13,251
Operating expenses                    
Consulting and management fees     2,302     3,671     11,876 9,232
Professional fees     453     (3)     2,301 3,884
General and administrative     442     352     1,646 3,287
Promotion and communication     1,104     1,308     4,710 8,033
Travel expenses     69     132     413 930
Share based compensation     10     654     1,591 3,404
Research and development     47     16     62 388
Operating lease expense     165     316     1,211 937
Depreciation and amortization     74     864     2,335 2,144
Bad debt expense     47     29     236 941
Asset impairment     898     0        
Goodwill impairment loss                 23,372 25,072
Other asset impairments                 16,135 709
Other expenses (income), net     728     377     2,204 1,511
Total operating expenses     6,339     7,716     68,092 60,472
Operating loss     (2,485)     (2,370)     (50,354) (47,221)
Interest expense     22     23     92 (29)
Foreign exchange (income) loss     132     (12)     (158) (323)
Unrealized (gain) loss from changes in fair value     607     883     (1,991) 593
Net loss before income taxes and discontinued operations     (3,246)     (3,264)     (48,297) (48,108)
Income tax benefit     128     (78)     (1,628) (1,405)
Net loss from continuing operations     (3,374)     (3,186)     (46,669) (46,703)
Loss from discontinued operations, net of taxes     0     (719)     (9,678) (5,926)
Net loss for the period     (3,374)     (3,905)     (56,347) (52,629)
Net income (loss) attributable to noncontrolling interest     0     (29)     689 (214)
Net loss attributable to Flora Growth Corp     $ (3,374)     $ (3,876)     $ (57,036) $ (52,415)
Basic loss per share from continuing operations | (per share) $ (0.38)     $ (0.48)         $ (6.34) $ (12.19)
Diluted loss per share from continuing operations | (per share) (0.38)     (0.48)         (6.34) (12.19)
Basic loss per share attributable to Flora Growth Corp. | (per share) (0.38)     (0.58)         (7.75) (13.68)
Diluted loss per share attributable to Flora Growth Corp. | (per share) $ (0.38)     $ (0.58)         $ (7.75) $ (13.68)
Weighted average number of common shares outstanding - basic | shares   8,916 8,916   6,640 6,640   7,356 7,356 3,832
Weighted average number of common shares outstanding - diluted | shares   8,916 8,916   6,640 6,640   7,356 7,356 3,832
Comprehensive loss:                    
Net loss     $ (3,374)     $ (3,905)     $ (56,347) $ (52,629)
Foreign currency translation, net of income taxes     (27)     (357)     (2,592) 1,624
Comprehensive loss for the period     (3,347)     (3,548)     (53,755) (54,253)
Comprehensive income (loss) attributable to noncontrolling interests     0     (29)     689 (214)
Comprehensive loss attributable to Flora Growth Corp.     $ (3,347)     $ (3,519)     $ (54,444) $ (54,039)
TruHC Pharma GmbH [Member]                    
Operating expenses                    
Professional fees | €   € 19,240     € 82   € 5,038 € 7,589    
General and administrative | €   47,089     26,207   113,458 210,622    
Travel expenses | €   326     425   451 2,037    
Operating lease expense | €   29,970     31,516   84,783 123,105    
Depreciation and amortization | €   3,742     1,933   9,550 14,675    
Operating loss | €   (100,181)     (60,163)   (213,280) (358,028)    
Interest expense | €   5,391     (270)   3,602 13,759    
Net loss for the period | €   (105,572)     (59,893)   (216,882) (371,787)    
Comprehensive loss:                    
Net loss | €   (105,572)     (59,893)   (216,882) (371,787)    
Comprehensive loss for the period | €   € (105,572)     € (59,893)   € (216,882) € (371,787)